Isolation of human monoclonal antibodies by mammalian cell display

Due to their low immunogenicity in patients, humanized or fully human mAbs are becoming increasingly important for the treatment of a growing number of diseases, including cancer, infections, and immune disorders. Here, we describe a technology allowing for the rapid isolation of fully human mAbs. In contrast to previously described methods, B cells specific for an antigen of interest are directly isolated from peripheral blood mononuclear cells (PBMC) of human donors. Recombinant, antigen-specific single-chain Fv (scFv) libraries are generated from this pool of B cells and screened by mammalian cell surface display by using a Sindbis virus expression system. This method allows isolating antigen-specific antibodies by a single round of FACS. The variable regions (VRs) of the heavy chains (HCs) and light chains (LCs) are isolated from positive clones and recombinant fully human antibodies produced as whole IgG or Fab fragments. In this manner, several hypermutated high-affinity antibodies binding the Qβ virus like particle (VLP), a model viral antigen, as well as antibodies specific for nicotine were isolated. All antibodies showed high expression levels in cell culture. The human nicotine-specific mAbs were validated preclinically in a mouse model. Thus, the technology presented here allows for rapid isolation of high-affinity, fully human antibodies with therapeutic potential from human volunteers.

[1]  Fkh.  Allergy, anaphylaxis, and immunotherapy, basic principles and practice , 1944 .

[2]  R. Levy,et al.  Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. , 1983, Blood.

[3]  A. Chaffotte,et al.  Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. , 1985, Journal of immunological methods.

[4]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[5]  T. Clackson,et al.  Making antibody fragments using phage display libraries , 1991, Nature.

[6]  C. Barbas,et al.  Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Winter,et al.  Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.

[8]  C. Rice,et al.  Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs , 1993, Journal of virology.

[9]  C. Borrebaeck,et al.  Single, antigen-specific B cells used to generate Fab fragments using CD40-mediated amplification or direct PCR cloning. , 1995, BioTechniques.

[10]  M. Taussig,et al.  Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. , 1997, Nucleic acids research.

[11]  A. Plückthun,et al.  In vitro selection and evolution of functional proteins by using ribosome display. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Banchereau,et al.  High Levels of Neutralizing Autoantibodies Against IL‐1α are Associated with a Better Prognosis in Chronic Polyarthritis: a Follow‐Up Study , 1997, Scandinavian journal of immunology.

[13]  Eric T. Boder,et al.  Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.

[14]  N. Benowitz,et al.  Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. , 1997, British journal of clinical pharmacology.

[15]  Larry L. Green,et al.  Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice , 1997, Nature Genetics.

[16]  Valérie Barbié,et al.  Protein Displays of the Human Immunoglobulin Heavy, Kappa and Lambda Variable and Joining Regions , 1999, Experimental and Clinical Immunogenetics.

[17]  Manqiu Cao,et al.  High-throughput generation and engineering of recombinant human antibodies. , 2001, Journal of immunological methods.

[18]  J. Bailey,et al.  A high-throughput alphavirus-based expression cloning system for mammalian cells , 2001, Nature Biotechnology.

[19]  Carlos F. Barbas,et al.  Phage display: a Laboratory manual , 2014 .

[20]  A. Fattom,et al.  Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome , 2001, Pharmacology Biochemistry and Behavior.

[21]  A. Johansson,et al.  Active Immunization against Nicotine Prevents Reinstatement of Nicotine-Seeking Behavior in Rats , 2002, Respiration.

[22]  Wang Jing-lin,et al.  In vitro selection and evolution of functional proteins by using ribosome display , 2003 .

[23]  J. Crowe,et al.  Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles. , 2003, Journal of immunological methods.

[24]  M. Bachmann,et al.  The Human Membrane Cofactor CD46 Is a Receptor for Species B Adenovirus Serotype 3 , 2004, Journal of Virology.

[25]  T. Sixma,et al.  Nicotine and Carbamylcholine Binding to Nicotinic Acetylcholine Receptors as Studied in AChBP Crystal Structures , 2004, Neuron.

[26]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[27]  K. Bendtzen,et al.  High levels of neutralizing IL‐6 autoantibodies in 0.1% of apparently healthy blood donors , 2004, European journal of immunology.

[28]  M. Bachmann,et al.  Rapid Response of Marginal Zone B Cells to Viral Particles , 2004, The Journal of Immunology.

[29]  H. Hoogenboom,et al.  Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.

[30]  M. Lesage,et al.  MONOCLONAL NICOTINE-SPECIFIC ANTIBODIES REDUCE NICOTINE DISTRIBUTION TO BRAIN IN RATS: DOSE- AND AFFINITY-RESPONSE RELATIONSHIPS , 2005, Drug Metabolism and Disposition.

[31]  G. Jennings,et al.  A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity , 2005, European journal of immunology.

[32]  N. Lonberg.  Human antibodies from transgenic animals , 2005, Nature Biotechnology.

[33]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[34]  P. S. Andersen,et al.  Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. , 2006, Journal of molecular biology.

[35]  Mitchell Ho,et al.  Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  George Georgiou,et al.  Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli , 2007, Nature Biotechnology.

[37]  D. Burton,et al.  Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. , 2007, Protein engineering, design & selection : PEDS.

[38]  M. Bachmann,et al.  Vaccination against nicotine: an emerging therapy for tobacco dependence , 2007, Expert opinion on investigational drugs.

[39]  H. Volk,et al.  Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study , 2008, The Lancet.